NKTR
Nektar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$74.19
−2.85%Aug 25, 2026, 12:30 UTC
Nektar Therapeutics announced the publication in The Lancet of positive Phase 2b REZOLVE-AD 16-week induction results for rezpegaldesleukin in moderate-to-severe atopic dermatitis, meeting all primary and key secondary endpoints.
Source:Aug 14, 2026, 02:04 UTC
Nektar Therapeutics finalized plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting with the U.S. Food and Drug Administration.
Source:Aug 14, 2026, 02:04 UTC
Nektar Therapeutics initiated its global Phase III ZENITH AD program for rezpegaldesleukin in moderate-to-severe atopic dermatitis during July 2026.
Source:Aug 11, 2026, 11:50 UTC
Kuehn Law, PLLC announced it is investigating potential breaches of fiduciary duty by officers and directors of Nektar Therapeutics, based on a federal securities lawsuit alleging misrepresentations about the REZOLVE-AA trial.
Source:Aug 11, 2026, 05:26 UTC
Nektar Therapeutics will release its Q2 2026 earnings after market close on Thursday, August 13th.
Jul 21, 2026, 11:00 UTC
Nektar Therapeutics initiated the first two global registrational Phase 3 trials (ZENITH AD-1 and ZENITH AD-2) in the ZENITH AD program for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Source: